Answers are grounded in this paper and cite their sources.
Study designs nanobody decoys to prevent autoantibody blocking in myasthenia gravis, suggesting a novel therapeutic approach.
To design nanobody-based decoys that mimic the α1-subunit of the acetylcholine receptor (AChR), preferentially binding to Immunoglobulin G1 (IgG1) autoantibodies, preventing antibody blocking and antigenic modulation in Myasthenia Gravis (MG).
No takes yet. Share an insight, caveat, or question.
Gavande et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: